A Study of LY3473329 in Healthy Participants

• Sponsor: Eli Lilly and Company (Industry)
• Overall Status: Completed
• CT.gov ID: NCT04472676
• Collaborator: (none)
• Enrollment: 86
• Location: 1
• Arms: 4
• Actual Duration (Months): 14.7
• Patients Per Site Per Month: 5.8

Study Details

Study Description

Brief Summary

The main purpose of this study in healthy participants is to learn more about the safety of LY3473329 and any side effects that might be associated with it. Blood tests will be performed to check how much LY3473329 gets into the bloodstream and how long the body takes to eliminate it. This is a two-part study. Participants may only enroll in one part.

For each participant:

• Part A will last up to about 19 weeks and may include 9 visits.

• Part B will last up to about 28 weeks and may include 11 visits.

Condition or Disease	Intervention/Treatment	Phase
Healthy	Drug: LY3473329; Drug: Placebo	Phase 1

Study Design

• Study Type: Interventional
• Actual Enrollment: 86 participants
• Allocation: Randomized
• Intervention Model: Sequential Assignment
• Masking: Double (Participant, Investigator)
• Primary Purpose: Basic Science
• Official Title: A Safety, Tolerability, and Pharmacokinetic Study of Single-and Multiple-Ascending Doses of LY3473329 in Healthy Subjects
• Actual Study Start Date: Aug 18, 2020
• Actual Primary Completion Date: Nov 9, 2021
• Actual Study Completion Date: Nov 9, 2021

Arms and Interventions

Arm	Intervention/Treatment
Experimental: LY3473329 (Part A) LY3473329 administered orally.	Drug: LY3473329; Administered orally.
Placebo Comparator: Placebo (Part A) Placebo administered orally.	Drug: Placebo; Administered orally.
Experimental: LY3473329 (Part B) LY3473329 administered orally.	Drug: LY3473329; Administered orally.
Experimental: Placebo (Part B) Placebo administered orally.	Drug: Placebo; Administered orally.

Outcome Measures

Primary Outcome Measures

1. Number of Participants with One or More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration [Baseline up to Day 137]

   A summary of SAEs and other non-serious adverse events (AEs), regardless of causality, will be reported in the Reported Adverse Events module

Secondary Outcome Measures

1. Pharmacokinetics (PK): Area Under the Concentration Versus Time Curve (AUC) of LY3473329 [Baseline up to Day 137]

   PK: AUC of LY3473329

2. PK: Maximum Observed Drug Concentration (Cmax) of LY3473329 [Baseline up to Day 137]

   PK: Cmax of LY3473329

Eligibility Criteria

Criteria

• Ages Eligible for Study: 18 Years to 54 Years
• Sexes Eligible for Study: All
• Accepts Healthy Volunteers: Yes

Inclusion Criteria:

• Males and females must adhere to contraception restrictions

• Have clinical laboratory test results within normal reference range or with acceptable deviations

• Body mass index (BMI) less than or equal to (≤)30 kilograms per square meter (kg/m²)

• For Part B:

• Lipoprotein (a) (Lp[a]) greater than or equal to (≥)75 nanomoles per Liter (nmol/L) or 30 milligrams per deciliter (mg/dL) at screening

• Plasminogen is within the normal range at screening

Exclusion Criteria:

• Are currently enrolled in, or discontinued within the past 30 days from, a clinical trial involving an investigational drug that has not received regulatory approval for any indication, except for any trial involving antisense Lp(a), for which 6 months must have passed from the participant's last study drug dose

• Have previously completed or withdrawn from this study or any other study investigating LY3473329

• Are pregnant or breast feeding

• Glomerular filtration rate (GFR) is lower than estimated GFR 60 milliliters per minute per 1.73 square meters (mL/min/1.73 m2) using the Modification of Diet in Renal Disease Study equation

• Have a history or presence of medical illness including, but not limited to, any cardiovascular, thromboembolism or bleeding disorder, hepatic, respiratory, hematological, endocrine, immune, psychiatric or neurological disease, convulsions, or any clinically significant laboratory abnormality that, in the judgment of the investigator, indicate a medical problem that would preclude study participation

• Have an abnormality in the 12-lead electrocardiogram (ECG) that, in the opinion of the investigator, increases the risks associated with participating in the study. In addition, participants with the following findings will be excluded: Confirmed Fridericia's corrected QT interval greater than (>)450 milliseconds (msec) for men and

470 msec for women. One additional ECG may be performed if required

• Have an elevated high-sensitivity C-reactive protein (>3 milligrams per Liter [mg/L]) or have a prothrombin time/international normalized ratio (PT/INR) or activated partial thromboplastin time (aPTT) >1.25 times (x) upper limit of normal (ULN)

• Are an investigator or site personnel directly affiliated or immediate families. Immediate family is defined as a spouse, parent, child or sibling, whether biological or legally adopted

• Are Lilly employees or contractors or an immediate family member of such

• Show evidence of human immunodeficiency virus (HIV) and/or positive human HIV antibodies, hepatitis C and/or positive hepatitis C antibody, or hepatitis B and/or positive hepatitis B surface antigen

• Have donated more than 500 milliliters (mL) of blood within the past month

• Are unwilling to stop alcohol consumption while resident in the clinical research unit (CRU)

• Have an average weekly alcohol intake that exceeds 21 units per week (1 unit = 12 ounces [oz] or 360 mL of beer; 5 oz or 150 mL of wine; 1.5 oz or 45 mL of distilled spirits)

• Have an abnormal blood pressure (supine) defined as diastolic blood pressure >95 or less than (<)45 millimeters of Mercury (mmHg) and/or systolic blood pressure >160 or <90 mmHg. Re-testing may occur once during screening within 2 hours of the initial abnormal blood pressure measurement at the discretion of the investigator at screening

• Have positive findings for known drugs of abuse on urinary drug screening

• Positive severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) virus nasopharyngeal polymerase chain reaction (PCR) test at Day -1

• Contact with SARS-CoV-2- positive or corona virus disease 2019 (COVID-19) patient within the last 14 days prior to admission to the clinical unit

• In the opinion of the investigator or the sponsor, are unsuitable for inclusion in the study

Contacts and Locations

Locations

	Site	City	State	Country	Postal Code
1	PRA Health Sciences	Groningen		Netherlands	9728

Sponsors and Collaborators

• Eli Lilly and Company

Investigators

• Study Director: Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST), Eli Lilly and Company

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.

• Responsible Party: Eli Lilly and Company
• ClinicalTrials.gov Identifier: NCT04472676
• Other Study ID Numbers: 17611; J2O-MC-EKBA; 2020-002522-91
• First Posted: Jul 15, 2020
• Last Update Posted: Dec 14, 2021
• Last Verified: Dec 1, 2021

• Individual Participant Data (IPD) Sharing Statement: No
• Plan to Share IPD: No
• Studies a U.S. FDA-regulated Drug Product: No
• Studies a U.S. FDA-regulated Device Product: No

Study Results

No Results Posted as of Dec 14, 2021